228 related articles for article (PubMed ID: 29192216)
21. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
22. Quiescence Promotes Latent HIV Infection and Resistance to Reactivation from Latency with Histone Deacetylase Inhibitors.
Painter MM; Zaikos TD; Collins KL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021396
[TBL] [Abstract][Full Text] [Related]
23. Dual TLR2 and TLR7 agonists as HIV latency-reversing agents.
Macedo AB; Novis CL; De Assis CM; Sorensen ES; Moszczynski P; Huang SH; Ren Y; Spivak AM; Jones RB; Planelles V; Bosque A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282829
[TBL] [Abstract][Full Text] [Related]
24. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
25. The mTOR Complex Controls HIV Latency.
Besnard E; Hakre S; Kampmann M; Lim HW; Hosmane NN; Martin A; Bassik MC; Verschueren E; Battivelli E; Chan J; Svensson JP; Gramatica A; Conrad RJ; Ott M; Greene WC; Krogan NJ; Siliciano RF; Weissman JS; Verdin E
Cell Host Microbe; 2016 Dec; 20(6):785-797. PubMed ID: 27978436
[TBL] [Abstract][Full Text] [Related]
26. An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients.
Spina CA; Anderson J; Archin NM; Bosque A; Chan J; Famiglietti M; Greene WC; Kashuba A; Lewin SR; Margolis DM; Mau M; Ruelas D; Saleh S; Shirakawa K; Siliciano RF; Singhania A; Soto PC; Terry VH; Verdin E; Woelk C; Wooden S; Xing S; Planelles V
PLoS Pathog; 2013; 9(12):e1003834. PubMed ID: 24385908
[TBL] [Abstract][Full Text] [Related]
27. 4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat.
De la Torre-Tarazona HE; Jiménez R; Bueno P; Camarero S; Román L; Fernández-García JL; Beltrán M; Nothias LF; Cachet X; Paolini J; Litaudon M; Alcami J; Bedoya LM
Biochem Pharmacol; 2020 Jul; 177():113937. PubMed ID: 32224142
[TBL] [Abstract][Full Text] [Related]
28. The HIV-1 Tat Protein: Mechanism of Action and Target for HIV-1 Cure Strategies.
Rice AP
Curr Pharm Des; 2017; 23(28):4098-4102. PubMed ID: 28677507
[TBL] [Abstract][Full Text] [Related]
29. Latent HIV-1 can be reactivated by cellular superinfection in a Tat-dependent manner, which can lead to the emergence of multidrug-resistant recombinant viruses.
Donahue DA; Bastarache SM; Sloan RD; Wainberg MA
J Virol; 2013 Sep; 87(17):9620-32. PubMed ID: 23804632
[TBL] [Abstract][Full Text] [Related]
30. Flavonoid-based inhibition of cyclin-dependent kinase 9 without concomitant inhibition of histone deacetylases durably reinforces HIV latency.
Schonhofer C; Yi J; Sciorillo A; Andrae-Marobela K; Cochrane A; Harris M; Brumme ZL; Brockman MA; Mounzer K; Hart C; Gyampoh K; Yuan Z; Montaner LJ; Tietjen I
Biochem Pharmacol; 2021 Apr; 186():114462. PubMed ID: 33577894
[TBL] [Abstract][Full Text] [Related]
31. Cyclin-dependent kinase 7 (CDK7)-mediated phosphorylation of the CDK9 activation loop promotes P-TEFb assembly with Tat and proviral HIV reactivation.
Mbonye U; Wang B; Gokulrangan G; Shi W; Yang S; Karn J
J Biol Chem; 2018 Jun; 293(26):10009-10025. PubMed ID: 29743242
[TBL] [Abstract][Full Text] [Related]
32. The BET inhibitor OTX015 reactivates latent HIV-1 through P-TEFb.
Lu P; Qu X; Shen Y; Jiang Z; Wang P; Zeng H; Ji H; Deng J; Yang X; Li X; Lu H; Zhu H
Sci Rep; 2016 Apr; 6():24100. PubMed ID: 27067814
[TBL] [Abstract][Full Text] [Related]
33. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
34. Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency.
Geng G; Liu B; Chen C; Wu K; Liu J; Zhang Y; Pan T; Li J; Yin Y; Zhang J; Huang F; Yu F; Chen J; Ma X; Zhou J; Kuang E; Liu C; Cai W; Zhang H
Mol Ther; 2016 Sep; 24(9):1528-37. PubMed ID: 27434587
[TBL] [Abstract][Full Text] [Related]
35. Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.
Xing S; Bhat S; Shroff NS; Zhang H; Lopez JA; Margolick JB; Liu JO; Siliciano RF
J Antimicrob Chemother; 2012 Feb; 67(2):398-403. PubMed ID: 22160146
[TBL] [Abstract][Full Text] [Related]
36. Thiostrepton Reactivates Latent HIV-1 through the p-TEFb and NF-κB Pathways Mediated by Heat Shock Response.
Peng W; Hong Z; Chen X; Gao H; Dai Z; Zhao J; Liu W; Li D; Deng K
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094131
[TBL] [Abstract][Full Text] [Related]
37. Disulfiram reactivates latent HIV-1 in a Bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.
Xing S; Bullen CK; Shroff NS; Shan L; Yang HC; Manucci JL; Bhat S; Zhang H; Margolick JB; Quinn TC; Margolis DM; Siliciano JD; Siliciano RF
J Virol; 2011 Jun; 85(12):6060-4. PubMed ID: 21471244
[TBL] [Abstract][Full Text] [Related]
38. Harmine enhances the activity of the HIV-1 latency-reversing agents ingenol A and SAHA.
Taylor JP; Armitage LH; Aldridge DL; Cash MN; Wallet MA
Biol Open; 2020 Dec; 9(12):. PubMed ID: 33234703
[TBL] [Abstract][Full Text] [Related]
39. Small Molecule Inhibitors of BAF; A Promising Family of Compounds in HIV-1 Latency Reversal.
Stoszko M; De Crignis E; Rokx C; Khalid MM; Lungu C; Palstra RJ; Kan TW; Boucher C; Verbon A; Dykhuizen EC; Mahmoudi T
EBioMedicine; 2016 Jan; 3():108-121. PubMed ID: 26870822
[TBL] [Abstract][Full Text] [Related]
40. A novel bromodomain inhibitor, CPI-203, serves as an HIV-1 latency-reversing agent by activating positive transcription elongation factor b.
Liang T; Zhang X; Lai F; Lin J; Zhou C; Xu X; Tan X; Liu S; Li L
Biochem Pharmacol; 2019 Jun; 164():237-251. PubMed ID: 30991051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
